ArrayExpress Uploader0human137.5not specified1807541PR0not specifiednot specified86Infiltrating Ductal Carcinomanot specified22Not Donenot specified013Faslodex 250mg205not specified80100not specifiedPR2.5not specifiednot specified3Infiltrating Ductal Carcinomanot specified34Not Donenot specified010Faslodex 500mg190not specified14020.50SD0not specifiednot specified25Infiltrating Ductal Carcinomanot specified75Poorly Differentiated(G3)not specified009Faslodex 250mg200not specified12427.5not specifiedPR0not specifiednot specified5Infiltrating Ductal Carcinomanot specified89Moderately Differentiated(G2)not specified008Faslodex 500mg165PR1457.5not specifiedNE7.5not specified1354Infiltrating Ductal Carcinoma268Poorly Differentiated(G3)0062Faslodex 500mg127.5not specified75127.5100SD29801057infiltrating lobular carcinoma1318Moderately Differentiated(G2)25059Faslodex 500mg140not specified75192.5not specifiedPR40not specifiednot specified1Infiltrating Ductal Carcinomanot specified13Poorly Differentiated(G3)not specified058Faslodex 500mg190not specified1450not specifiedPR0not specified1007Infiltrating Ductal Carcinoma18Poorly Differentiated(G3)5057Faslodex 500mg65SD55055NE096not specified28Infiltrating Ductal Carcinomanot specified30Moderately Differentiated(G2)not specified056Faslodex 250mg185not specified10560not specifiedSD22.5not specifiednot specified11Infiltrating Ductal Carcinomanot specified46Moderately Differentiated(G2)not specified007Faslodex 250mg220not specified157.53not specifiedSD1not specifiednot specified4Infiltrating Ductal Carcinomanot specified61Moderately Differentiated(G2)not specified055Faslodex 250mg95not specified600200SD0not specifiednot specified19infiltrating lobular carcinomanot specified17Moderately Differentiated(G2)not specified054Faslodex 500mg145not specified47.552.596SD0not specified6045infiltrating lobular carcinoma9118Unassessable(GX)0053Faslodex 250mg127.5not specified950not specifiedSD030not specified22Infiltrating Ductal Carcinomanot specified34Poorly Differentiated(G3)not specified051Faslodex 500mg100not specified67.5125not specifiedSD13not specified3511Infiltrating Ductal Carcinomanot specified6Moderately Differentiated(G2)not specified050Faslodex 250mg160not specified1250not specifiedNE0not specifiednot specified11Infiltrating Ductal Carcinomanot specified26Moderately Differentiated(G2)not specified049Faslodex 500mg162.5not specified0142.5not specifiedSD0not specifiednot specifiednot specifiedinfiltrating lobular carcinomanot specified55Moderately Differentiated(G2)not specified048Faslodex 500mg155not specified1117.5not specifiedSD0not specified03Other217Not Done0047Faslodex 500mg200not specified1250not specifiedPR0not specifiednot specified15Undifferentiated Carcinomanot specified91Not Donenot specified044Faslodex 500mg195not specified122.53not specifiedPR3not specifiednot specified10infiltrating lobular carcinomanot specified50Unassessable(GX)not specified042Faslodex 500mg125not specified37.560not specifiedSD15not specifiednot specified17infiltrating lobular carcinomanot specified44Moderately Differentiated(G2)not specified006Faslodex 500mg0not specified107.50not specifiedPR42.5not specifiednot specified15Infiltrating Ductal Carcinomanot specified61Moderately Differentiated(G2)not specified041Faslodex 250mg147.5PR82.5195not specifiedPD17.5not specifiednot specified22Infiltrating Ductal Carcinomanot specified33Not Donenot specified040Faslodex 500mg195not specified19532.534SD0not specifiednot specified57Infiltrating Ductal Carcinomanot specified69Not Donenot specified039Faslodex 250mg160not specified900not specifiedPR0not specifiednot specified3Infiltrating Ductal Carcinomanot specified59Unassessable(GX)not specified037Faslodex 250mg207.5not specified167.565not specifiedPR0not specifiednot specified4Infiltrating Ductal Carcinomanot specified51Moderately Differentiated(G2)not specified036Faslodex 500mg175not specified1955200SD7510013529Infiltrating Ductal Carcinoma23Well Differentiated(G1)7.5033Faslodex 250mg180not specified140100not specifiedSD4021152.51Infiltrating Ductal Carcinoma25Moderately Differentiated(G2)1.5031Faslodex 500mg152.5not specified112.560not specifiedSD0not specifiednot specified5Infiltrating Ductal Carcinomanot specified28Moderately Differentiated(G2)not specified030Faslodex 250mg152.5not specified130180not specifiedSD105not specifiednot specified18Infiltrating Ductal Carcinomanot specified69Poorly Differentiated(G3)not specified029Faslodex 500mg90not specified8030not specifiedPR30not specifiednot specified2Infiltrating Ductal Carcinomanot specified1Moderately Differentiated(G2)not specified005Faslodex 500mg157.5not specified107.5132.5not specifiedSD18.5not specifiednot specified36Infiltrating Ductal Carcinomanot specified56Poorly Differentiated(G3)not specified028Faslodex 250mg195not specified125165200SD75194not specified4Infiltrating Ductal Carcinomanot specified19Moderately Differentiated(G2)not specified027Faslodex 500mg150not specified11065not specifiedSD9.5not specifiednot specified10Infiltrating Ductal Carcinomanot specified50Moderately Differentiated(G2)not specified025Faslodex 250mg0SD00100PD0not specifiednot specified97Infiltrating Ductal Carcinomanot specified100Moderately Differentiated(G2)not specified024Faslodex 250mg1not specified8.50not specifiedPR0200not specified71Infiltrating Ductal Carcinomanot specified45Poorly Differentiated(G3)not specified021Faslodex 250mg239not specified220110200PR12200not specified1Infiltrating Ductal Carcinomanot specified77Moderately Differentiated(G2)not specified020Faslodex 500mg190not specified180225not specifiedPR170not specifiednot specified7Infiltrating Ductal Carcinomanot specified37Poorly Differentiated(G3)not specified019Faslodex 250mg182.5not specified10050not specifiedPR0not specifiednot specified3Infiltrating Ductal Carcinomanot specified66Moderately Differentiated(G2)not specified018Faslodex 500mg150not specified155150not specifiedSD0not specified1255Infiltrating Ductal Carcinoma3756Moderately Differentiated(G2)0015Faslodex 250mg230not specified170125not specifiedSD80not specified2.56Infiltrating Ductal Carcinoma365Moderately Differentiated(G2)55014Faslodex 250mg180not specified1454.5not specifiedSD0not specifiednot specified19Infiltrating Ductal Carcinomanot specified22Moderately Differentiated(G2)not specified004Faslodex 250mg2148arrayexpress_sid4The NEWEST (Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumours) trial compared the clinical and biological...E-GEOD-48905/profile/8773/arrayexpressuploader1742breastdiseaseestrogenvolumeDec.12, 2014Falsethe-newest-trialE-GEOD-48905_A-AFFY-44The NEWEST trialJul.11, 2014The NEWEST (Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumours) trial compared the clinical and biological activity of fulvestrant 500 mg vs 250 mg in the neoadjuvant setting. In this multi-centre phase II study, post-menopausal women with operable, locally advanced (T2, 3, 4b; N0-3; M0) ER-positive breast tumours were randomised to receive neoadjuvant treatment with either dose of fulvestrant for 16 weeks before surgery. Tumour core biopsies were obtained at baseline, 4 weeks and at surgery for assessment of changes in biomarker expression. Tumour volumes were measured by 3-D ultrasound at the same timepoints. In this trial, the percentage of patients who showed a reduction in tumour volume or stabilisation of disease (using RECIST criteria) after treatment with fulvestrant 500 mg was 36% (26 out of 69 patients). Therefore, within a population of endocrine-therapy naive patients whose tumours were confirmed as being ER-positive at the time of study entry, there is a subgroup who gained particular clinical benefit from fulvestrant treatment. These clinical response data together with the availability of biological response information and frozen tumour tissue from participants makes the NEWEST trial an attractive setting in which to investigate the potential of new markers of response to fulvestrant. 42 sampleshttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-48905http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-48905/samples/